Polyrizon Ltd. filed a Form D with the Securities and Exchange Commission on 2026-09-10.
Polyrizon Ltd. filed a Form D notice of an exempt securities offering with the SEC on September 10, 2026. The filing reports $4M sold. Its industry group is Biotechnology. It names Tomer Izraeli (Chief Executive Officer and Director), Nir Yosef (Chief Financial Officer), Eyal Ron (Chief Science Officer) (SEC Form D, September 10, 2026).
Sell to companies like Polyrizon Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Polyrizon Ltd.
Free to see. No signup.
More on the people and the money behind Polyrizon Ltd., from the filings we hold.
Biotechnology raises by companies based in Israel, filed within 90 days of this one, largest first.
Get an email when Polyrizon Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Polyrizon Ltd. raises, hires or launches. No email unless you switch it on.
Watch Polyrizon Ltd. →Get the full cited report on Polyrizon Ltd.
What the filing shows about Polyrizon Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Polyrizon Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Polyrizon Ltd. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $4M, on the same scale — one filing against the whole group's total, so it sits low by construction.
The Company intends to use the net proceeds, together with existing cash, for general corporate purposes, including financing operations, capital expenditures, business development and technology development, and pursuing strategic opportunities.
By form type: 6-K ×69 · CORRESP ×27 · UPLOAD ×18 · F-1/A ×14 · 3 ×9 · 4 ×6 · EFFECT ×6 · SCHEDULE 13G ×5, and others.
| Form | Filed | On EDGAR |
|---|---|---|
| D | 2026-09-10 | open |
| 6-K | 2026-09-04 | open |
| 6-K | 2026-09-04 | open |
| 424B5 | 2026-09-04 | open |
| 6-K | 2026-08-20 | open |
| SCHEDULE 13G/A | 2026-08-14 | open |
| 6-K | 2026-07-13 | open |
| 6-K | 2026-07-02 | open |
| 6-K | 2026-06-29 | open |
| 6-K | 2026-06-17 | open |
What the filing shows about Polyrizon Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Polyrizon Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Polyrizon Ltd. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 10 most recent of 190 filings on CIK 0001893645, filed as Polyrizon Ltd.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in L3. Full history on sec.gov.
Checked away from the filing. What is below does not come from the record on sec.gov.
Polyrizon is a biotech company, focused on the development and commercialization of innovative intranasal products based on the Company’s technology platforms.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
On the filing as: Executive Officer, Director.
Tomer Izraeli is named as Chief Executive Officer and Director on the Form D that Polyrizon Ltd. filed with the SEC on 10 September 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Nir Yosef is named as Chief Financial Officer on the Form D that Polyrizon Ltd. filed with the SEC on 10 September 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Eyal Ron is named as Chief Science Officer on the Form D that Polyrizon Ltd. filed with the SEC on 10 September 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Tidhar Turgeman is named as Chief Technology Officer on the Form D that Polyrizon Ltd. filed with the SEC on 10 September 2026, one of 9 people that filing names.
Asaf Itzhaik is named as Director on the Form D that Polyrizon Ltd. filed with the SEC on 10 September 2026, one of 9 people that filing names.
Oz Adler is named as Director on the Form D that Polyrizon Ltd. filed with the SEC on 10 September 2026, one of 9 people that filing names.
Liat Sidi is named as Director on the Form D that Polyrizon Ltd. filed with the SEC on 10 September 2026, one of 9 people that filing names.
Yehonatan Vinokur is named as Director on the Form D that Polyrizon Ltd. filed with the SEC on 10 September 2026, one of 9 people that filing names.
Liron Carmel is named as Director on the Form D that Polyrizon Ltd. filed with the SEC on 10 September 2026, one of 9 people that filing names.
9 people named on the filing — 4 holding an executive role and 5 as directors only.
Named as of the 2026-09-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Polyrizon Ltd.You get an alert in MentionFox the next time this company shows up.
If you're behind Polyrizon Ltd.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-25 (polyrizon-biotech.com).
Each opens in a new tab, filled in for Polyrizon Ltd.. With no account yet, you sign up free and land on the result.
On these lists: Outside the US raises, week of 2026-09-07 · Biotech raises, week of 2026-09-07
https://mentionfox.com/funding/polyrizon-ltd-form-d-098803